Relief Therapeutics Holding AG
RLFTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1 | $3 | $6 | $3 |
| % Growth | -55.9% | -51.1% | 87.8% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $8 |
| Gross Profit | $1 | $2 | $4 | -$5 |
| % Margin | 50.8% | 63.3% | 72.4% | -170.8% |
| R&D Expenses | $1 | $1 | $1 | $0 |
| G&A Expenses | $1 | $7 | $2 | $2 |
| SG&A Expenses | $4 | $4 | $6 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1 |
| Other Operating Expenses | $0 | $12 | $1 | $0 |
| Operating Expenses | $5 | $17 | $8 | $3 |
| Operating Income | -$4 | -$15 | -$4 | -$99 |
| % Margin | -363.3% | -539.5% | -70.4% | -3,295.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $52 |
| Pre-Tax Income | -$5 | -$15 | -$4 | -$48 |
| Tax Expense | $0 | -$3 | $1 | -$6 |
| Net Income | -$4 | -$13 | -$5 | -$42 |
| % Margin | -367.7% | -454.7% | -80.6% | -1,384.8% |
| EPS | -0.36 | -1 | -0.36 | -3.32 |
| % Growth | 64% | -177.8% | 89.2% | – |
| EPS Diluted | -0.36 | -1 | -0.36 | -3.32 |
| Weighted Avg Shares Out | 13 | 13 | 13 | 13 |
| Weighted Avg Shares Out Dil | 13 | 13 | 13 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $2 |
| EBITDA | -$4 | -$14 | -$3 | -$7 |
| % Margin | -329.6% | -508.1% | -44.9% | -220.7% |